Sugi Predict

Sugi Predict / Compounds / SCHEMBL4916787

SCHEMBL4916787

SCHEMBL4916787

CCOc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 20/20 0.81
▸ PRKD3 O94806 2/20 0.81
▸ MAP4K4 O95819 2/20 0.81
▸ PRKCA P17252 2/20 0.81
▸ CSNK1A1 P48729 2/20 0.81
▸ CSNK1D P48730 2/20 0.81
▸ MINK1 Q8N4C8 2/20 0.81
▸ MAP4K5 Q9Y4K4 2/20 0.81
▸ MAPK11 Q15759 2/20 0.81
▸ KDM4E B2RXH2 1/20 0.81
▸ MAPK13 O15264 1/20 0.81
▸ EGFR P00533 1/20 0.81
▸ RAF1 P04049 1/20 0.81
▸ CYP1A2 P05177 1/20 0.81
▸ LCK P06239 1/20 0.81
▸ CYP2D6 P10635 1/20 0.81
▸ CYP2C9 P11712 1/20 0.81
▸ CYP2C19 P33261 1/20 0.81
▸ FRK P42685 1/20 0.81
▸ MAPK9 P45984 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916783 1.00 MAPK14 (0.81) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL8477798 0.90 MAPK14 (0.78) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL173596 0.90 MAPK14 (1.00) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL173595 0.90 MAPK14 (1.00) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL30290594 0.90 MAPK14 (1.00) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL4918359 0.90 MAPK14 (1.00) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL8478684 0.89 MAPK14 (0.80) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL8478682 0.89 MAPK14 (0.80) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL4916756 0.89 MAPK14 (1.00) MAPK14PRKD3MAP4K4PRKCACSNK1A1
SCHEMBL6578729 0.89 MAPK14 (0.79) MAPK14PRKD3MAP4K4PRKCACSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase SCIOS INC. 2006-01-26 — — US disclosed
US-20050129729-A1 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. 2005-06-16 — — US disclosed
WO-2005032551-A1 TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE SCIOS INC. (US) 2005-04-14 — — WO disclosed
WO-2005030091-A2 STENTS AND INTRA-LUMINAL PROSTHESES CONTAINING MAP KINASE INHIBITORS SCIOS INC. (US) 2005-04-07 — — WO disclosed
EP-0889726-B1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORP (US) 2004-09-15 — — EP disclosed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 — — US disclosed
US-20040162289-A1 Methods of promoting osteogenesis UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY 2004-08-19 — — US disclosed
WO-2004019873-A9 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2004-06-24 — — WO disclosed
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase SCIOS, INC. 2004-06-24 — — US disclosed
US-6387898-B1 USING IMIDAZOLE COMPOUND SMITHKLINE BEECHAM CORPORATION 2002-05-14 — — US disclosed
US-6329526-B1 Cycloalkyl substituted imidazoles SMITHKLINE BEECHAM CORPORATION 2001-12-11 — — US disclosed
US-6251914-B1 TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2001-06-26 — — US disclosed
US-6096739-A Treatment for CNS injuries SMITHKLINE BEECHAM CORPORATION (US) 2000-08-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase MAPKAPK5, MAPK1, MAPKAPK2 MAPK14 36/4885PRKD3 117/4885MAP4K4 32/4885
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MAPK14 23/4885PRKD3 196/4885MAP4K4 55/4885
US-20040162289-A1 Methods of promoting osteogenesis MAPK1, BMP2, MAPK3 MAPK14 23/4885PRKD3 196/4885MAP4K4 55/4885
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885PRKD3 568/4885MAP4K4 37/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885PRKD3 568/4885MAP4K4 37/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 MAPK14 53/4885PRKD3 232/4885MAP4K4 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.